Concerns about the use of long-acting opioids such as methadone often center on the risk of extended respiratory depression. However, clinical studies have not shown an increased incidence of respiratory depression or hypoxemia with methadone compared to controls in post-anesthesia care units, surgical wards, or intensive care units. Similarly, retrospective studies report no severe respiratory events with intraoperative methadone use, and there has been no need for naloxone infusions to reverse prolonged respiratory depression.
Further clinical evidence suggests methadone's safety profile concerning other opioid-related side effects mirrors that of traditional opioids. Research evaluating postoperative sedation levels and the occurrence of nausea and vomiting postoperatively found no significant differences between patients receiving methadone and those treated with standard opioids. Additionally, no methadone-related adverse cardiac events have been documented, and its effect on bowel function appears neutral when compared to other opioids. It is important to highlight that these findings come from relatively small studies, which might not fully capture rare events or the effects in high-risk populations, underlining the need for further large-scale research.
There are isolated reports of prolonged methadone effects, such as a case from 1976 involving an elderly patient experiencing extended respiratory depression after a high dose of methadone, requiring repeated naloxone administration. A larger retrospective review also reported a notable incidence of respiratory depression and hypoxemia in patients receiving methadone for major spine surgeries, but the study lacked a control group for comparison.
Methadone's inhibition of the serotonin transporter at clinical doses has been linked to serotonin syndrome in chronic use cases, particularly when combined with other serotonergic drugs. While perioperative intravenous methadone has not been associated with serotonin syndrome, vigilance is advised when administering methadone to patients on antidepressants to avoid potential serotonergic complications.
| Concern | What the clinical evidence shows |
|---|---|
| Respiratory depression / hypoxemia | No increased incidence versus controls in PACU, surgical wards, or ICUs; however, one larger uncontrolled retrospective review of major spine surgery reported a notable incidence of respiratory depression and hypoxemia |
| Need for naloxone infusion | No naloxone infusions required in the reported series; an isolated 1976 case of an elderly patient given a high dose needed repeated naloxone boluses |
| Postoperative sedation | No significant difference versus standard opioids |
| Nausea and vomiting | No significant difference versus standard opioids |
| Cardiac adverse events | None documented as methadone-related |
| Bowel function | Neutral effect compared with other opioids |
| Serotonin syndrome | Not associated with perioperative IV methadone, but remain vigilant in patients on antidepressants |
| QT prolongation | Risk arises mainly from the higher doses used in chronic treatment, not the single lower perioperative dose |
